Technical Analysis for DRRX - DURECT Corporation

Grade Last Price % Change Price Change
F 1.68 0.60% 0.01
DRRX closed up 0.6 percent on Thursday, May 13, 2021, on 56 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical DRRX trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish 0.60%
180 Bearish Setup Bearish Swing Setup 0.60%
20 DMA Resistance Bearish 0.00%
20 DMA Resistance Bearish -4.55%
Down 3 Days in a Row Weakness -2.33%
Fell Below 20 DMA Bearish -5.08%
Earnings Movers Other -5.08%
Overbought Stochastic Strength -5.08%
Older End-of-Day Signals for DRRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 20 hours ago
Up 2% about 21 hours ago
Up 1% about 21 hours ago
Bearish 180 Entry about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

DURECT Corporation Description

DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. It focuses on the development of products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, cardiovascular disease, and other chronic diseases. The company manufactures and sells ALZET osmotic pumps used in laboratory research; and a range of LACTEL standard and custom biodegradable polymers and excipients used as raw materials for the pharmaceutical and medical device clients. Its product pipeline includes REMOXY, an oral oxycodone gelatin capsule for chronic pain, which has received complete response letter from the U.S. Food and Drug Administration (FDA); POSIDUR, a Phase III clinical trial release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR, a Phase II transdermal sufentanil patch intended to provide delivery of sufentanil. The company's products pipeline also comprises ORADUR-based opioids, including hydrocodone and hydromorphone for the treatment of pain, which are in Phase I clinical trial; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It is also involved in developing various biologics programs/research programs in other therapeutic categories. DURECT Corporation has strategic agreements with Hospira, Inc., Nycomed Danmark ApS; Pain Therapeutics, Inc.; Zogenix, Inc.; and Pfizer Inc. The company was founded in 1998 and is headquartered in Cupertino, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pain Chemical Compounds Organic Compounds Polymers Symptoms Opioid Schizophrenia Cardiovascular Disease Drug Delivery Euphoriants FDA Chronic Pain Nervous System Disorders Central Nervous System Disorders Ethers Morphinans Chronic Disease Opioids Attention Deficit Attention Deficit Hyperactivity Disorder Pharmaceutical And Medical Chronic Diseases Hyperactivity Disorder Transdermal Excipients Pharmaceutical And Medical Device Bupivacaine Hydrocodone Phenols Adhd Drug Delivery Technology Fentanyl Treatment Of Attention Deficit Hyperactivity Disorder Excipient Oxycodone Hydromorphone Oxymorphone Relday Sufentanil

Is DRRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.947
52 Week Low 1.52
Average Volume 1,035,477
200-Day Moving Average 2.00
50-Day Moving Average 1.92
20-Day Moving Average 1.76
10-Day Moving Average 1.76
Average True Range 0.10
ADX 28.34
+DI 10.80
-DI 23.58
Chandelier Exit (Long, 3 ATRs ) 1.64
Chandelier Exit (Short, 3 ATRs ) 1.88
Upper Bollinger Band 1.93
Lower Bollinger Band 1.58
Percent B (%b) 0.27
BandWidth 19.84
MACD Line -0.06
MACD Signal Line -0.05
MACD Histogram -0.0028
Fundamentals Value
Market Cap 341.34 Million
Num Shares 203 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -11.13
Price-to-Sales 8.58
Price-to-Book 10.72
PEG Ratio -0.46
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.79
Resistance 3 (R3) 1.79 1.76 1.77
Resistance 2 (R2) 1.76 1.73 1.76 1.76
Resistance 1 (R1) 1.72 1.72 1.74 1.72 1.76
Pivot Point 1.69 1.69 1.70 1.69 1.69
Support 1 (S1) 1.65 1.66 1.67 1.65 1.60
Support 2 (S2) 1.62 1.65 1.62 1.60
Support 3 (S3) 1.58 1.62 1.59
Support 4 (S4) 1.58